行情

NKTR

NKTR

内克塔治疗
NASDAQ

实时行情|Nasdaq Last Sale

18.42
+0.83
+4.72%
交易中 13:56 04/08 EDT
开盘
17.84
昨收
17.59
最高
18.67
最低
17.50
成交量
63.01万
成交额
--
52周最高
37.00
52周最低
13.63
市值
32.71亿
市盈率(TTM)
-7.3139
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NKTR价格均价为31.92,最高价位80.00,最低价为18.00。

EPS

NKTR 新闻

更多
  • Need To Know: Analysts Are Much More Bullish On Nektar Therapeutics (NASDAQ:NKTR) Revenues
  • Simply Wall St. · 2天前
  • Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
  • seekingalpha · 2天前
  • Medicenna's Potential Best-In-Class IL-2 Superkine Program Making Progress
  • Seeking Alpha - Article · 04/01 01:58
  • Benzinga's Top Upgrades, Downgrades For March 30, 2020
  • Benzinga · 03/30 13:35

所属板块

生物技术和医学研究
+1.77%
制药与医学研究
+1.60%

热门股票

代码
价格
涨跌幅

NKTR 简况

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
展开

微牛提供Nektar Therapeutics(NASDAQ-NKTR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NKTR股票新闻,以帮助您做出投资决策。